The retest period is the timeframe during which a drug substance is expected to remain within its specifications under defined storage conditions; the retest date is the cut-off date derived from this for a specific batch. After this date, the drug substance may only be used after retesting and must then be processed immediately.<\/p>\n
The retest period is derived from formal stability studies, not from the manufacturing date or general storage experience. These studies examine relevant quality-determining characteristics over time under the intended storage conditions. For a drug substance, content, degradation products, water content, crystal form, or microbial properties may be critical, depending on its nature and the dosage form in the subsequent medicinal product.<\/p>\n
This information is only valid in conjunction with the underlying conditions, such as temperature, humidity, and container. If a container is opened multiple times after sampling or transferred to another container, the original stability assumption cannot be extended without evaluation. A transport event outside the permissible temperature also requires classification against the available data.<\/p>\n
The retest date does not necessarily mark the disposal of the batch. It signals that its conformity with the specification must be re-demonstrated before it is used for manufacturing. The retest must cover the characteristics relevant to age-related quality loss and be performed within the approved analytical framework.<\/p>\n
A successful retest result does not legitimize an indefinite extension of use. The batch must be processed immediately after testing because the stability decision refers to the specifically tested state. Repeated retests as a substitute for an adequate stability program would undermine the time logic derived from the studies.<\/p>\n
The derivation can include accelerated and, if applicable, intermediate stability data in addition to long-term data. They should not be read in isolation: an accelerated trend can show which test characteristics need particularly close monitoring in the long-term study. The stability-indicating nature of an analytical method is crucial so that an observed loss or a new degradation product is not masked by the method itself.<\/p>\n
For batch management, the assignment is clear: retest date, storage condition, container status, and certificates of analysis must all pertain to the same drug substance batch. If material is split, the storage and sampling documentation needs to link the sub-container to the original batch. A correct retest date on an incorrect sub-container does not solve the identity problem.<\/p>\n
Quality risk often arises at handover points. A laboratory may plan timely testing, while production relies on a different material date. Material status management must therefore reflect the retest date as controlling information and not just as a text field.<\/p>\n
The retest period concerns the drug substance and is not the same as the shelf life or expiry date of a finished medicinal product. For the finished product, the stability assessment additionally considers the formulation and the final container-closure system; there, the expiry date describes the last day of permissible use. For labile biological substances and certain antibiotics, a fixed shelf life instead of a retest concept is therefore appropriate.<\/p>\n
For repackaged comparators in clinical trials, the retest date becomes additionally relevant if the original labeling cannot simply be adopted or if the storage history needs to be evaluated. The new label must not create a stability statement that is not covered by the data of the starting product. Clinical labeling and manufacturing documentation must therefore consistently reflect the chosen cut-off date. The detailed Commission guidelines C(2017) 8179 final stipulate for this case that an appropriate retest date, considering product characteristics, container characteristics, and storage conditions, is to be determined and justified by the sponsor or on their behalf; it must not be later than the expiry date of the original package and must be suitable for the duration of the clinical trial.<\/p>\n
A retest date may only be derived from the approved stability assessment. A short-term extension to cover a production bottleneck would not be permissible without suitable data and formal evaluation.<\/p>\n
A drug substance can be manufactured long before the start of a study and only later called upon for the production of a new investigational medicinal product batch. Procurement and manufacturing planning must therefore consider the retest period alongside material availability, release deadlines, and planned dosages. If the cut-off date is reached during a campaign, a missing retest can directly delay the provision of study medication.<\/p>\n
Full-service CROs like Mediconomics support the coordination of CMC timelines, material status, and labeling data for investigational medicinal products and comparators. They can manage communication between the sponsor, drug substance manufacturer, packaging facility, and clinical supply chain to ensure that retest results are identified before the intended processing and not only upon shipment.<\/p>\n
Is a retest date identical to an expiry date?<\/strong><\/p>\n No. The retest date requires retesting of the drug substance before further processing, whereas an expiry date denotes the end point of the approved period of use for a finished product.<\/p>\n Which storage conditions belong to the retest period?<\/strong><\/p>\n Exactly those conditions apply for which the stability data support the period. This may include requirements for temperature, humidity, light protection, and container.<\/p>\n May a batch remain stored for a long time after passing a retest?<\/strong><\/p>\n No. After retesting, it should be processed immediately. For later use, the stability situation must be re-evaluated.<\/p>\n The retest period is the timeframe during which a drug substance is expected to remain within its specifications under defined storage conditions; the retest date is the cut-off date derived from this for a specific batch. After this date, the drug substance may only be used after retesting and must then be processed immediately. Stability […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[26],"class_list":["post-8185","glossary","type-glossary","status-publish","hentry","glossary-cat-gmp-qualitaet-herstellung"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8185","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/8185\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=8185"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=8185"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n